Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders
Benoît Drolet(Hôpital du Saint-Sacrement), Jacques Turgeon(Académie Nationale de Médecine), Pascal Daleau(Hôpital du Saint-Sacrement), Guy Rousseau(Hôpital du Sacré-Cœur de Montréal), René Cardinal(Hôpital du Saint-Sacrement)
Cited by 164
Related Papers
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
|Pharmaceutics|2020|237
The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis
|International Journal of Molecular Sciences|2021|200
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
|Annals of Pharmacotherapy|2013|186